MEDICINOVA INC. - COMMON STOCK

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe

14 May 2023 19:00:00 By Nasdaq GlobeNewswire

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada

30 Apr 2023 19:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

09 Mar 2023 18:00:00 By Nasdaq GlobeNewswire

MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics

20 Feb 2023 18:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID

08 Feb 2023 18:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder

30 Jan 2023 18:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma

12 Jan 2023 18:00:00 By Nasdaq GlobeNewswire

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada

10 Jan 2023 22:00:00 By Nasdaq GlobeNewswire

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil

09 Jan 2023 22:00:00 By Nasdaq GlobeNewswire

MediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral Formulation of MN-166 (ibudilast)

05 Jan 2023 18:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation

06 Dec 2022 18:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Positive Results from Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) Published in The American Journal of Drug and Alcohol Abuse

05 Dec 2022 18:00:00 By Nasdaq GlobeNewswire

MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference

15 Sep 2022 19:00:00 By Nasdaq GlobeNewswire

MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma

14 Sep 2022 19:00:00 By Nasdaq GlobeNewswire

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada

13 Sep 2022 19:00:00 By Nasdaq GlobeNewswire

MediciNova Reaches Agreement to Participate in Grant-Funded Clinical Trial to Evaluate MN-166 (ibudilast) for the Treatment of Long COVID

16 Aug 2022 06:30:00 By Nasdaq GlobeNewswire

MediciNova Announces MN-001 (tipelukast) Abstract regarding Improvement of Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Accepted for Presentation at the IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation

09 Aug 2022 19:00:00 By Nasdaq GlobeNewswire

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea

27 Jul 2022 06:30:00 By Nasdaq GlobeNewswire

MediciNova Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia

26 Jul 2022 06:30:00 By Nasdaq GlobeNewswire

MediciNova Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast)

21 Jul 2022 19:00:00 By Nasdaq GlobeNewswire